0001127602-19-025555.txt : 20190731
0001127602-19-025555.hdr.sgml : 20190731
20190731175603
ACCESSION NUMBER: 0001127602-19-025555
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190729
FILED AS OF DATE: 20190731
DATE AS OF CHANGE: 20190731
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kuntz Richard
CENTRAL INDEX KEY: 0001341125
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36820
FILM NUMBER: 19990089
MAIL ADDRESS:
STREET 1: MEDTRONIC, INC.
STREET 2: 710 MEDTRONIC PWKY MS LC 310
CITY: MINNEAPOLIS
STATE: MN
ZIP: 55432
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Medtronic plc
CENTRAL INDEX KEY: 0001613103
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 000000000
FISCAL YEAR END: 0426
BUSINESS ADDRESS:
STREET 1: 20 ON HATCH, LOWER HATCH STREET
CITY: DUBLIN
STATE: L2
ZIP: 2
BUSINESS PHONE: 01135314381700
MAIL ADDRESS:
STREET 1: 20 ON HATCH, LOWER HATCH STREET
CITY: DUBLIN
STATE: L2
ZIP: 2
FORMER COMPANY:
FORMER CONFORMED NAME: Medtronic Ltd
DATE OF NAME CHANGE: 20150112
FORMER COMPANY:
FORMER CONFORMED NAME: Medtronic Holdings Ltd
DATE OF NAME CHANGE: 20140711
FORMER COMPANY:
FORMER CONFORMED NAME: Kalani I Ltd
DATE OF NAME CHANGE: 20140709
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2019-07-29
0001613103
Medtronic plc
MDT
0001341125
Kuntz Richard
710 MEDTRONIC PKWY MS LC300
MINNEAPOLIS
MN
55432
1
SVP & Chief Medical & Science
Ordinary Shares
2019-07-29
4
A
0
10330
0
A
110755
D
Stock Option (Right to Buy)
103.26
2019-07-29
4
A
0
68901
0
A
2020-07-29
2029-07-29
Ordinary Shares
68901
68901
D
Stock Option (Right to Buy)
103.26
2019-07-29
4
A
0
1615
0
A
2020-07-29
2029-07-29
Ordinary Shares
1615
1615
D
The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2022 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee.
This balance increased by 298 shares due to exempt transactions such as dividend reinvestment.
These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant.
/s/ Perry F. Sekus, attorney-in-fact
2019-07-31